News/ News/ R&D Novo-backed $61m fundraising helps F2G prep for antifungal launch Phil Taylor antifungal, antifungal resistance, F2G, financing, infectious disease, Novo Holdings 0 Comment Anglo-Austrian biotech F2G has raised $60.8 million in venture financing to help it bring a drug for life-threatening Share X Novo-backed $61m fundraising helps F2G prep for antifungal launch https://pharmaphorum.com/news/novo-backed-61m-fundraising-helps-f2g-prep-for-antifungal-launch/
News/ News/ R&D FDA tags F2G’s olorofim as Breakthrough Therapy for fungal infections Richard Staines F2G, fda, R&D 0 Comment The US drugs regulator has tagged F2G’s olorofim as a potential Breakthrough Therapy for life-threatening fungal infections, pledging Share X FDA tags F2G’s olorofim as Breakthrough Therapy for fungal infections https://pharmaphorum.com/news/fda-tags-f2gs-olorofilm-as-breakthrough-therapy-for-mould-infections/